ID

DB15101||

名称

Tigatuzumab

描述

Tigatuzumab is under investigation in clinical trial NCT00991796 (CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)).

cas号

918127-53-4

唯一标识码

237GB6IDKO

状态

组

investigational,

指示

药效学

作用机制

毒性

代谢

吸收

半衰期

分类

消除途径

种类

Amino Acids, Peptides, and Proteins
D000602
Antibodies
D000906
Antibodies, Monoclonal
D000911
Blood Proteins
D001798
Globulins
D005916
Immunoglobulins
D007136
Immunoproteins
D007162
Proteins
D011506
Serum Globulins
D012712

盐类

蛋白质结合

清除

同义词

国际品牌

配送量

产品

混合物

包装者

生产者

价格

受影响的生物体

剂量

atc代码

fda标签

化学品安全技术说明书

专利

食物相互作用

药物相互作用

DB00255
Diethylstilbestrol may increase the thrombogenic activities of Tigatuzumab.
DB00269
Chlorotrianisene may increase the thrombogenic activities of Tigatuzumab.
DB00286
Conjugated estrogens may increase the thrombogenic activities of Tigatuzumab.
DB00655
Estrone may increase the thrombogenic activities of Tigatuzumab.
DB00783
Estradiol may increase the thrombogenic activities of Tigatuzumab.
DB00890
Dienestrol may increase the thrombogenic activities of Tigatuzumab.
DB00977
Ethinylestradiol may increase the thrombogenic activities of Tigatuzumab.
DB01357
Mestranol may increase the thrombogenic activities of Tigatuzumab.
DB04573
Estriol may increase the thrombogenic activities of Tigatuzumab.
DB04574
Estrone sulfate may increase the thrombogenic activities of Tigatuzumab.
DB04575
Quinestrol may increase the thrombogenic activities of Tigatuzumab.
DB07931
Hexestrol may increase the thrombogenic activities of Tigatuzumab.
DB09070
Tibolone may increase the thrombogenic activities of Tigatuzumab.
DB09317
Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Tigatuzumab.
DB09318
Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Tigatuzumab.
DB09369
Polyestradiol phosphate may increase the thrombogenic activities of Tigatuzumab.
DB09381
Esterified estrogens may increase the thrombogenic activities of Tigatuzumab.
DB11478
Zeranol may increase the thrombogenic activities of Tigatuzumab.
DB11674
Equol may increase the thrombogenic activities of Tigatuzumab.
DB12487
Promestriene may increase the thrombogenic activities of Tigatuzumab.
DB13143
Methallenestril may increase the thrombogenic activities of Tigatuzumab.
DB13386
Epimestrol may increase the thrombogenic activities of Tigatuzumab.
DB13418
Moxestrol may increase the thrombogenic activities of Tigatuzumab.
DB13952
Estradiol acetate may increase the thrombogenic activities of Tigatuzumab.
DB13953
Estradiol benzoate may increase the thrombogenic activities of Tigatuzumab.
DB13954
Estradiol cypionate may increase the thrombogenic activities of Tigatuzumab.
DB13956
Estradiol valerate may increase the thrombogenic activities of Tigatuzumab.
DB15334
Biochanin A may increase the thrombogenic activities of Tigatuzumab.
DB15335
Formononetin may increase the thrombogenic activities of Tigatuzumab.
DB00002
The risk or severity of adverse effects can be increased when Cetuximab is combined with Tigatuzumab.
DB00028
The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tigatuzumab.
DB00043
The risk or severity of adverse effects can be increased when Omalizumab is combined with Tigatuzumab.
DB00051
The risk or severity of adverse effects can be increased when Adalimumab is combined with Tigatuzumab.
DB00054
The risk or severity of adverse effects can be increased when Abciximab is combined with Tigatuzumab.
DB00056
The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tigatuzumab.
DB00057
The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tigatuzumab.
DB00065
The risk or severity of adverse effects can be increased when Infliximab is combined with Tigatuzumab.
DB00072
The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tigatuzumab.
DB00073
The risk or severity of adverse effects can be increased when Rituximab is combined with Tigatuzumab.
DB00074
The risk or severity of adverse effects can be increased when Basiliximab is combined with Tigatuzumab.
DB00075
The risk or severity of adverse effects can be increased when Muromonab is combined with Tigatuzumab.
DB00076
The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tigatuzumab.
DB00078
The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tigatuzumab.
DB00081
The risk or severity of adverse effects can be increased when Tositumomab is combined with Tigatuzumab.
DB00087
The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tigatuzumab.
DB00089
The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tigatuzumab.
DB00095
The risk or severity of adverse effects can be increased when Efalizumab is combined with Tigatuzumab.
DB00098
The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tigatuzumab.
DB00108
The risk or severity of adverse effects can be increased when Natalizumab is combined with Tigatuzumab.
DB00110
The risk or severity of adverse effects can be increased when Palivizumab is combined with Tigatuzumab.
DB00111
The risk or severity of adverse effects can be increased when Daclizumab is combined with Tigatuzumab.
DB00112
The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tigatuzumab.
DB00113
The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tigatuzumab.
DB01257
The risk or severity of adverse effects can be increased when Eculizumab is combined with Tigatuzumab.
DB01269
The risk or severity of adverse effects can be increased when Panitumumab is combined with Tigatuzumab.
DB01270
The risk or severity of adverse effects can be increased when Ranibizumab is combined with Tigatuzumab.
DB04901
The risk or severity of adverse effects can be increased when Galiximab is combined with Tigatuzumab.
DB04949
The risk or severity of adverse effects can be increased when Pexelizumab is combined with Tigatuzumab.
DB04956
The risk or severity of adverse effects can be increased when Afelimomab is combined with Tigatuzumab.
DB04958
The risk or severity of adverse effects can be increased when Epratuzumab is combined with Tigatuzumab.
DB04962
The risk or severity of adverse effects can be increased when Bectumomab is combined with Tigatuzumab.
DB04964
The risk or severity of adverse effects can be increased when Oregovomab is combined with Tigatuzumab.
DB04988
The risk or severity of adverse effects can be increased when IGN311 is combined with Tigatuzumab.
DB05006
The risk or severity of adverse effects can be increased when Adecatumumab is combined with Tigatuzumab.
DB05097
The risk or severity of adverse effects can be increased when Labetuzumab is combined with Tigatuzumab.
DB05101
The risk or severity of adverse effects can be increased when Matuzumab is combined with Tigatuzumab.
DB05111
The risk or severity of adverse effects can be increased when Fontolizumab is combined with Tigatuzumab.
DB05136
The risk or severity of adverse effects can be increased when Bavituximab is combined with Tigatuzumab.
DB05139
The risk or severity of adverse effects can be increased when CR002 is combined with Tigatuzumab.
DB05209
The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Tigatuzumab.
DB05304
The risk or severity of adverse effects can be increased when Girentuximab is combined with Tigatuzumab.
DB05336
The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Tigatuzumab.
DB05405
The risk or severity of adverse effects can be increased when XTL-001 is combined with Tigatuzumab.
DB05437
The risk or severity of adverse effects can be increased when NAV 1800 is combined with Tigatuzumab.
DB05459
The risk or severity of adverse effects can be increased when Briakinumab is combined with Tigatuzumab.
DB05496
The risk or severity of adverse effects can be increased when Otelixizumab is combined with Tigatuzumab.
DB05545
The risk or severity of adverse effects can be increased when AMG 108 is combined with Tigatuzumab.
DB05550
The risk or severity of adverse effects can be increased when Iratumumab is combined with Tigatuzumab.
DB05555
The risk or severity of adverse effects can be increased when Enokizumab is combined with Tigatuzumab.
DB05578
The risk or severity of adverse effects can be increased when Ramucirumab is combined with Tigatuzumab.
DB05595
The risk or severity of adverse effects can be increased when Farletuzumab is combined with Tigatuzumab.
DB05656
The risk or severity of adverse effects can be increased when Veltuzumab is combined with Tigatuzumab.
DB05679
The risk or severity of adverse effects can be increased when Ustekinumab is combined with Tigatuzumab.
DB05773
The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Tigatuzumab.
DB05793
The risk or severity of adverse effects can be increased when PRO-542 is combined with Tigatuzumab.
DB05797
The risk or severity of adverse effects can be increased when TNX-901 is combined with Tigatuzumab.
DB05889
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tigatuzumab.
DB05892
The risk or severity of adverse effects can be increased when RI 624 is combined with Tigatuzumab.
DB05915
The risk or severity of adverse effects can be increased when MYO-029 is combined with Tigatuzumab.
DB05916
The risk or severity of adverse effects can be increased when CT-011 is combined with Tigatuzumab.
DB05941
The risk or severity of adverse effects can be increased when Leronlimab is combined with Tigatuzumab.
DB05996
The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Tigatuzumab.
DB06043
The risk or severity of adverse effects can be increased when Olaratumab is combined with Tigatuzumab.
DB06049
The risk or severity of adverse effects can be increased when IPH 2101 is combined with Tigatuzumab.
DB06050
The risk or severity of adverse effects can be increased when TB-402 is combined with Tigatuzumab.
DB06081
The risk or severity of adverse effects can be increased when Caplacizumab is combined with Tigatuzumab.
DB06101
The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Tigatuzumab.
DB06116
The risk or severity of adverse effects can be increased when Eldelumab is combined with Tigatuzumab.
DB06162
The risk or severity of adverse effects can be increased when Lumiliximab is combined with Tigatuzumab.
DB06168
The risk or severity of adverse effects can be increased when Canakinumab is combined with Tigatuzumab.
DB06186
The risk or severity of adverse effects can be increased when Ipilimumab is combined with Tigatuzumab.
DB06192
The risk or severity of adverse effects can be increased when Nimotuzumab is combined with Tigatuzumab.
DB06241
The risk or severity of adverse effects can be increased when Clenoliximab is combined with Tigatuzumab.
DB06273
The risk or severity of adverse effects can be increased when Tocilizumab is combined with Tigatuzumab.
DB06304
The risk or severity of adverse effects can be increased when BIIB015 is combined with Tigatuzumab.
DB06305
The risk or severity of adverse effects can be increased when Sonepcizumab is combined with Tigatuzumab.
DB06310
The risk or severity of adverse effects can be increased when Motavizumab is combined with Tigatuzumab.
DB06317
The risk or severity of adverse effects can be increased when Elotuzumab is combined with Tigatuzumab.
DB06318
The risk or severity of adverse effects can be increased when AVE9633 is combined with Tigatuzumab.
DB06322
The risk or severity of adverse effects can be increased when Carotuximab is combined with Tigatuzumab.
DB06324
The risk or severity of adverse effects can be increased when XmAb 2513 is combined with Tigatuzumab.
DB06342
The risk or severity of adverse effects can be increased when Coltuximab ravtansine is combined with Tigatuzumab.
DB06343
The risk or severity of adverse effects can be increased when Teprotumumab is combined with Tigatuzumab.
DB06360
The risk or severity of adverse effects can be increased when Lucatumumab is combined with Tigatuzumab.
DB06366
The risk or severity of adverse effects can be increased when Pertuzumab is combined with Tigatuzumab.
DB06371
The risk or severity of adverse effects can be increased when Siplizumab is combined with Tigatuzumab.
DB06467
The risk or severity of adverse effects can be increased when Apolizumab is combined with Tigatuzumab.
DB06474
The risk or severity of adverse effects can be increased when Sibrotuzumab is combined with Tigatuzumab.
DB06550
The risk or severity of adverse effects can be increased when Bivatuzumab is combined with Tigatuzumab.
DB06557
The risk or severity of adverse effects can be increased when Lerdelimumab is combined with Tigatuzumab.
DB06599
The risk or severity of adverse effects can be increased when Lexatumumab is combined with Tigatuzumab.
DB06602
The risk or severity of adverse effects can be increased when Reslizumab is combined with Tigatuzumab.
DB06606
The risk or severity of adverse effects can be increased when Teplizumab is combined with Tigatuzumab.
DB06607
The risk or severity of adverse effects can be increased when Catumaxomab is combined with Tigatuzumab.
DB06612
The risk or severity of adverse effects can be increased when Mepolizumab is combined with Tigatuzumab.
DB06643
The risk or severity of adverse effects can be increased when Denosumab is combined with Tigatuzumab.
DB06647
The risk or severity of adverse effects can be increased when Volociximab is combined with Tigatuzumab.
DB06650
The risk or severity of adverse effects can be increased when Ofatumumab is combined with Tigatuzumab.
DB06674
The risk or severity of adverse effects can be increased when Golimumab is combined with Tigatuzumab.
DB08870
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tigatuzumab.
DB08879
The risk or severity of adverse effects can be increased when Belimumab is combined with Tigatuzumab.
DB08902
The risk or severity of adverse effects can be increased when Raxibacumab is combined with Tigatuzumab.
DB08904
The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Tigatuzumab.
DB08935
The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Tigatuzumab.
DB09029
The risk or severity of adverse effects can be increased when Secukinumab is combined with Tigatuzumab.
DB09033
The risk or severity of adverse effects can be increased when Vedolizumab is combined with Tigatuzumab.
DB09035
The risk or severity of adverse effects can be increased when Nivolumab is combined with Tigatuzumab.
DB09036
The risk or severity of adverse effects can be increased when Siltuximab is combined with Tigatuzumab.
DB09037
The risk or severity of adverse effects can be increased when Pembrolizumab is combined with Tigatuzumab.
DB09045
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Tigatuzumab.
DB09052
The risk or severity of adverse effects can be increased when Blinatumomab is combined with Tigatuzumab.
DB09057
The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Tigatuzumab.
DB09077
The risk or severity of adverse effects can be increased when Dinutuximab is combined with Tigatuzumab.
DB09105
The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Tigatuzumab.
DB09264
The risk or severity of adverse effects can be increased when Idarucizumab is combined with Tigatuzumab.
DB09302
The risk or severity of adverse effects can be increased when Alirocumab is combined with Tigatuzumab.
DB09303
The risk or severity of adverse effects can be increased when Evolocumab is combined with Tigatuzumab.
DB09312
The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Tigatuzumab.
DB09331
The risk or severity of adverse effects can be increased when Daratumumab is combined with Tigatuzumab.
DB09559
The risk or severity of adverse effects can be increased when Necitumumab is combined with Tigatuzumab.
DB11569
The risk or severity of adverse effects can be increased when Ixekizumab is combined with Tigatuzumab.
DB11580
The risk or severity of adverse effects can be increased when Ravulizumab is combined with Tigatuzumab.
DB11595
The risk or severity of adverse effects can be increased when Atezolizumab is combined with Tigatuzumab.
DB11604
The risk or severity of adverse effects can be increased when Tetanus Immune Globulin is combined with Tigatuzumab.
DB11608
The risk or severity of adverse effects can be increased when Eftrenonacog alfa is combined with Tigatuzumab.
DB11621
The risk or severity of adverse effects can be increased when Human Varicella-Zoster Immune Globulin is combined with Tigatuzumab.
DB11646
The risk or severity of adverse effects can be increased when Conatumumab is combined with Tigatuzumab.
DB11657
The risk or severity of adverse effects can be increased when Tabalumab is combined with Tigatuzumab.
DB11680
The risk or severity of adverse effects can be increased when Ficlatuzumab is combined with Tigatuzumab.
DB11685
The risk or severity of adverse effects can be increased when Figitumumab is combined with Tigatuzumab.
DB11714
The risk or severity of adverse effects can be increased when Durvalumab is combined with Tigatuzumab.
DB11715
The risk or severity of adverse effects can be increased when Bapineuzumab is combined with Tigatuzumab.
DB11731
The risk or severity of adverse effects can be increased when Depatuxizumab mafodotin is combined with Tigatuzumab.
DB11746
The risk or severity of adverse effects can be increased when Onartuzumab is combined with Tigatuzumab.
DB11756
The risk or severity of adverse effects can be increased when Solanezumab is combined with Tigatuzumab.
DB11767
The risk or severity of adverse effects can be increased when Sarilumab is combined with Tigatuzumab.
DB11771
The risk or severity of adverse effects can be increased when Tremelimumab is combined with Tigatuzumab.
DB11776
The risk or severity of adverse effects can be increased when Brodalumab is combined with Tigatuzumab.
DB11803
The risk or severity of adverse effects can be increased when Sirukumab is combined with Tigatuzumab.
DB11826
The risk or severity of adverse effects can be increased when Lampalizumab is combined with Tigatuzumab.
DB11834
The risk or severity of adverse effects can be increased when Guselkumab is combined with Tigatuzumab.
DB11840
The risk or severity of adverse effects can be increased when Dalotuzumab is combined with Tigatuzumab.
DB11849
The risk or severity of adverse effects can be increased when Emibetuzumab is combined with Tigatuzumab.
DB11850
The risk or severity of adverse effects can be increased when Ublituximab is combined with Tigatuzumab.
DB11856
The risk or severity of adverse effects can be increased when Ligelizumab is combined with Tigatuzumab.
DB11857
The risk or severity of adverse effects can be increased when Seribantumab is combined with Tigatuzumab.
DB11862
The risk or severity of adverse effects can be increased when Landogrozumab is combined with Tigatuzumab.
DB11866
The risk or severity of adverse effects can be increased when Romosozumab is combined with Tigatuzumab.
DB11884
The risk or severity of adverse effects can be increased when Vadastuximab Talirine is combined with Tigatuzumab.
DB11914
The risk or severity of adverse effects can be increased when Lebrikizumab is combined with Tigatuzumab.
DB11930
The risk or severity of adverse effects can be increased when Varlilumab is combined with Tigatuzumab.
DB11945
The risk or severity of adverse effects can be increased when Avelumab is combined with Tigatuzumab.
DB11959
The risk or severity of adverse effects can be increased when Crenezumab is combined with Tigatuzumab.
DB11972
The risk or severity of adverse effects can be increased when Rilotumumab is combined with Tigatuzumab.
DB11976
The risk or severity of adverse effects can be increased when Anifrolumab is combined with Tigatuzumab.
DB11988
The risk or severity of adverse effects can be increased when Ocrelizumab is combined with Tigatuzumab.
DB12023
The risk or severity of adverse effects can be increased when Benralizumab is combined with Tigatuzumab.
DB12034
The risk or severity of adverse effects can be increased when Gantenerumab is combined with Tigatuzumab.
DB12053
The risk or severity of adverse effects can be increased when Visilizumab is combined with Tigatuzumab.
DB12077
The risk or severity of adverse effects can be increased when Urelumab is combined with Tigatuzumab.
DB12089
The risk or severity of adverse effects can be increased when Lorvotuzumab mertansine is combined with Tigatuzumab.
DB12090
The risk or severity of adverse effects can be increased when Patritumab is combined with Tigatuzumab.
DB12102
The risk or severity of adverse effects can be increased when Fulranumab is combined with Tigatuzumab.
DB12104
The risk or severity of adverse effects can be increased when Tarextumab is combined with Tigatuzumab.
DB12118
The risk or severity of adverse effects can be increased when Sotatercept is combined with Tigatuzumab.
DB12119
The risk or severity of adverse effects can be increased when Gevokizumab is combined with Tigatuzumab.
DB12142
The risk or severity of adverse effects can be increased when Duligotuzumab is combined with Tigatuzumab.
DB12152
The risk or severity of adverse effects can be increased when Simtuzumab is combined with Tigatuzumab.
DB12157
The risk or severity of adverse effects can be increased when Fasinumab is combined with Tigatuzumab.
DB12159
The risk or severity of adverse effects can be increased when Dupilumab is combined with Tigatuzumab.
DB12169
The risk or severity of adverse effects can be increased when Tralokinumab is combined with Tigatuzumab.
DB12189
The risk or severity of adverse effects can be increased when Etrolizumab is combined with Tigatuzumab.
DB12202
The risk or severity of adverse effects can be increased when Zalutumumab is combined with Tigatuzumab.
DB12205
The risk or severity of adverse effects can be increased when Ganitumab is combined with Tigatuzumab.
DB12213
The risk or severity of adverse effects can be increased when Etaracizumab is combined with Tigatuzumab.
DB12240
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Tigatuzumab.
DB12246
The risk or severity of adverse effects can be increased when Inclacumab is combined with Tigatuzumab.
DB12250
The risk or severity of adverse effects can be increased when Cixutumumab is combined with Tigatuzumab.
DB12261
The risk or severity of adverse effects can be increased when Ascrinvacumab is combined with Tigatuzumab.
DB12274
The risk or severity of adverse effects can be increased when Aducanumab is combined with Tigatuzumab.
DB12281
The risk or severity of adverse effects can be increased when Luspatercept is combined with Tigatuzumab.
DB12296
The risk or severity of adverse effects can be increased when GS-5745 is combined with Tigatuzumab.
DB12317
The risk or severity of adverse effects can be increased when Vanucizumab is combined with Tigatuzumab.
DB12331
The risk or severity of adverse effects can be increased when Labetuzumab govitecan is combined with Tigatuzumab.
DB12335
The risk or severity of adverse effects can be increased when Tanezumab is combined with Tigatuzumab.
DB12342
The risk or severity of adverse effects can be increased when Ensituximab is combined with Tigatuzumab.
DB12344
The risk or severity of adverse effects can be increased when Fezakinumab is combined with Tigatuzumab.
DB12363
The risk or severity of adverse effects can be increased when Dusigitumab is combined with Tigatuzumab.
DB12396
The risk or severity of adverse effects can be increased when Fresolimumab is combined with Tigatuzumab.
DB12413
The risk or severity of adverse effects can be increased when Indusatumab vedotin is combined with Tigatuzumab.
DB12456
The risk or severity of adverse effects can be increased when Bococizumab is combined with Tigatuzumab.
DB12489
The risk or severity of adverse effects can be increased when Mirvetuximab Soravtansine is combined with Tigatuzumab.
DB12498
The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Tigatuzumab.
DB12520
The risk or severity of adverse effects can be increased when Plozalizumab is combined with Tigatuzumab.
DB12530
The risk or severity of adverse effects can be increased when Inebilizumab is combined with Tigatuzumab.
DB12534
The risk or severity of adverse effects can be increased when Mavrilimumab is combined with Tigatuzumab.
DB12560
The risk or severity of adverse effects can be increased when Blosozumab is combined with Tigatuzumab.
DB12584
The risk or severity of adverse effects can be increased when Bimagrumab is combined with Tigatuzumab.
DB12589
The risk or severity of adverse effects can be increased when Dacetuzumab is combined with Tigatuzumab.
DB12609
The risk or severity of adverse effects can be increased when Tovetumab is combined with Tigatuzumab.
DB12683
The risk or severity of adverse effects can be increased when Lumretuzumab is combined with Tigatuzumab.
DB12698
The risk or severity of adverse effects can be increased when Ibalizumab is combined with Tigatuzumab.
DB12701
The risk or severity of adverse effects can be increased when Intetumumab is combined with Tigatuzumab.
DB12718
The risk or severity of adverse effects can be increased when Carlumab is combined with Tigatuzumab.
DB12734
The risk or severity of adverse effects can be increased when Demcizumab is combined with Tigatuzumab.
DB12773
The risk or severity of adverse effects can be increased when Sifalimumab is combined with Tigatuzumab.
DB12775
The risk or severity of adverse effects can be increased when Abituzumab is combined with Tigatuzumab.
DB12797
The risk or severity of adverse effects can be increased when Ecromeximab is combined with Tigatuzumab.
DB12807
The risk or severity of adverse effects can be increased when Naptumomab Estafenatox is combined with Tigatuzumab.
DB12815
The risk or severity of adverse effects can be increased when Crotedumab is combined with Tigatuzumab.
DB12820
The risk or severity of adverse effects can be increased when Concizumab is combined with Tigatuzumab.
DB12826
The risk or severity of adverse effects can be increased when Depatuxizumab is combined with Tigatuzumab.
DB12844
The risk or severity of adverse effects can be increased when Rontalizumab is combined with Tigatuzumab.
DB12845
The risk or severity of adverse effects can be increased when Amatuximab is combined with Tigatuzumab.
DB12849
The risk or severity of adverse effects can be increased when Clazakizumab is combined with Tigatuzumab.
DB12891
The risk or severity of adverse effects can be increased when Ozanezumab is combined with Tigatuzumab.
DB12893
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Tigatuzumab.
DB12917
The risk or severity of adverse effects can be increased when Bimekizumab is combined with Tigatuzumab.
DB12943
The risk or severity of adverse effects can be increased when Milatuzumab is combined with Tigatuzumab.
DB12976
The risk or severity of adverse effects can be increased when Robatumumab is combined with Tigatuzumab.
DB13017
The risk or severity of adverse effects can be increased when Rovalpituzumab Tesirine is combined with Tigatuzumab.
DB13037
The risk or severity of adverse effects can be increased when Namilumab is combined with Tigatuzumab.
DB13045
The risk or severity of adverse effects can be increased when Racotumomab is combined with Tigatuzumab.
DB13073
The risk or severity of adverse effects can be increased when Tregalizumab is combined with Tigatuzumab.
DB13127
The risk or severity of adverse effects can be increased when Olokizumab is combined with Tigatuzumab.
DB13140
The risk or severity of adverse effects can be increased when Bezlotoxumab is combined with Tigatuzumab.
DB13375
The risk or severity of adverse effects can be increased when Edrecolomab is combined with Tigatuzumab.
DB13535
The risk or severity of adverse effects can be increased when Nebacumab is combined with Tigatuzumab.
DB13886
The risk or severity of adverse effects can be increased when Human cytomegalovirus immune globulin is combined with Tigatuzumab.
DB13923
The risk or severity of adverse effects can be increased when Emicizumab is combined with Tigatuzumab.
DB13976
The risk or severity of adverse effects can be increased when Sulesomab is combined with Tigatuzumab.
DB13979
The risk or severity of adverse effects can be increased when Besilesomab is combined with Tigatuzumab.
DB14004
The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Tigatuzumab.
DB14012
The risk or severity of adverse effects can be increased when Burosumab is combined with Tigatuzumab.
DB14039
The risk or severity of adverse effects can be increased when Erenumab is combined with Tigatuzumab.
DB14040
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Tigatuzumab.
DB14041
The risk or severity of adverse effects can be increased when Fremanezumab is combined with Tigatuzumab.
DB14042
The risk or severity of adverse effects can be increased when Galcanezumab is combined with Tigatuzumab.
DB14211
The risk or severity of adverse effects can be increased when Fanolesomab is combined with Tigatuzumab.
DB14580
The risk or severity of adverse effects can be increased when Lecanemab is combined with Tigatuzumab.
DB14597
The risk or severity of adverse effects can be increased when Lanadelumab is combined with Tigatuzumab.
DB14707
The risk or severity of adverse effects can be increased when Cemiplimab is combined with Tigatuzumab.
DB14724
The risk or severity of adverse effects can be increased when Emapalumab is combined with Tigatuzumab.
DB14762
The risk or severity of adverse effects can be increased when Risankizumab is combined with Tigatuzumab.
DB14776
The risk or severity of adverse effects can be increased when Camrelizumab is combined with Tigatuzumab.
DB14778
The risk or severity of adverse effects can be increased when Setrusumab is combined with Tigatuzumab.
DB14784
The risk or severity of adverse effects can be increased when Gancotamab is combined with Tigatuzumab.
DB14809
The risk or severity of adverse effects can be increased when Anetumab ravtansine is combined with Tigatuzumab.
DB14811
The risk or severity of adverse effects can be increased when Isatuximab is combined with Tigatuzumab.
DB14824
The risk or severity of adverse effects can be increased when Icrucumab is combined with Tigatuzumab.
DB14843
The risk or severity of adverse effects can be increased when Codrituzumab is combined with Tigatuzumab.
DB14864
The risk or severity of adverse effects can be increased when Brolucizumab is combined with Tigatuzumab.
DB14871
The risk or severity of adverse effects can be increased when Xentuzumab is combined with Tigatuzumab.
DB14877
The risk or severity of adverse effects can be increased when Lintuzumab is combined with Tigatuzumab.
DB14891
The risk or severity of adverse effects can be increased when Vobarilizumab is combined with Tigatuzumab.
DB14897
The risk or severity of adverse effects can be increased when Parsatuzumab is combined with Tigatuzumab.
DB14905
The risk or severity of adverse effects can be increased when Emactuzumab is combined with Tigatuzumab.
DB14907
The risk or severity of adverse effects can be increased when Bevacizumab zirconium Zr-89 is combined with Tigatuzumab.
DB14908
The risk or severity of adverse effects can be increased when Refanezumab is combined with Tigatuzumab.
DB14919
The risk or severity of adverse effects can be increased when Rozanolixizumab is combined with Tigatuzumab.
DB14947
The risk or severity of adverse effects can be increased when Bermekimab is combined with Tigatuzumab.
DB14952
The risk or severity of adverse effects can be increased when Pamrevlumab is combined with Tigatuzumab.
DB14959
The risk or severity of adverse effects can be increased when Opicinumab is combined with Tigatuzumab.
DB14962
The risk or severity of adverse effects can be increased when Trastuzumab deruxtecan is combined with Tigatuzumab.
DB14967
The risk or severity of adverse effects can be increased when Margetuximab is combined with Tigatuzumab.
DB14988
The risk or severity of adverse effects can be increased when Dalantercept is combined with Tigatuzumab.
DB14997
The risk or severity of adverse effects can be increased when Pateclizumab is combined with Tigatuzumab.
DB15014
The risk or severity of adverse effects can be increased when Gremubamab is combined with Tigatuzumab.
DB15022
The risk or severity of adverse effects can be increased when Apomab is combined with Tigatuzumab.
DB15044
The risk or severity of adverse effects can be increased when Tafasitamab is combined with Tigatuzumab.
DB15045
The risk or severity of adverse effects can be increased when Ipafricept is combined with Tigatuzumab.
DB15076
The risk or severity of adverse effects can be increased when Abrilumab is combined with Tigatuzumab.
DB15089
The risk or severity of adverse effects can be increased when Frovocimab is combined with Tigatuzumab.
DB15090
The risk or severity of adverse effects can be increased when Tezepelumab is combined with Tigatuzumab.
DB15104
The risk or severity of adverse effects can be increased when Tigatuzumab is combined with Telisotuzumab vedotin.
DB15113
The risk or severity of adverse effects can be increased when Tigatuzumab is combined with Utomilumab.
DB15118
The risk or severity of adverse effects can be increased when Tigatuzumab is combined with Zolbetuximab.
DB15135
The risk or severity of adverse effects can be increased when Tigatuzumab is combined with Ponezumab.
DB15160
The risk or severity of adverse effects can be increased when Tigatuzumab is combined with Asunercept.
DB15172
The risk or severity of adverse effects can be increased when Tigatuzumab is combined with Suvratoxumab.
DB15225
The risk or severity of adverse effects can be increased when Tigatuzumab is combined with Mitazalimab.
DB15252
The risk or severity of adverse effects can be increased when Tigatuzumab is combined with Nemolizumab.
DB15253
The risk or severity of adverse effects can be increased when Tigatuzumab is combined with Bleselumab.
DB15277
The risk or severity of adverse effects can be increased when Tigatuzumab is combined with Gedivumab.
DB15336
The risk or severity of adverse effects can be increased when Tigatuzumab is combined with Valanafusp alfa.
DB15349
The risk or severity of adverse effects can be increased when Tigatuzumab is combined with Sofituzumab vedotin.
DB15354
The risk or severity of adverse effects can be increased when Tigatuzumab is combined with Evinacumab.
DB15363
The risk or severity of adverse effects can be increased when Tigatuzumab is combined with Istiratumab.
DB15383
The risk or severity of adverse effects can be increased when Tigatuzumab is combined with Pidilizumab.
DB15397
The risk or severity of adverse effects can be increased when Tigatuzumab is combined with GMA-161.
DB15409
The risk or severity of adverse effects can be increased when Tigatuzumab is combined with Ladiratuzumab vedotin.
DB15415
The risk or severity of adverse effects can be increased when Tigatuzumab is combined with Tomaralimab.
DB15428
The risk or severity of adverse effects can be increased when Tigatuzumab is combined with Vesencumab.
DB15432
The risk or severity of adverse effects can be increased when Tigatuzumab is combined with Pinatuzumab vedotin.
DB15441
The risk or severity of adverse effects can be increased when Tigatuzumab is combined with Lulizumab pegol.
DB15443
The risk or severity of adverse effects can be increased when Tigatuzumab is combined with Lorukafusp alfa.
DB15453
The risk or severity of adverse effects can be increased when Tigatuzumab is combined with Naratuximab emtansine.
DB15559
The risk or severity of adverse effects can be increased when Tigatuzumab is combined with Zenocutuzumab.
DB15898
The risk or severity of adverse effects can be increased when Tigatuzumab is combined with Atoltivimab.
DB15899
The risk or severity of adverse effects can be increased when Tigatuzumab is combined with Maftivimab.
DB15900
The risk or severity of adverse effects can be increased when Tigatuzumab is combined with Odesivimab.
DB15719
The risk or severity of adverse effects can be increased when Tigatuzumab is combined with Belantamab mafodotin.
DB15595
The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Tigatuzumab.
DB15258
The therapeutic efficacy of Tigatuzumab can be decreased when used in combination with Imlifidase.

序列

实验性质

外部标识符

resource：Wikipedia
identifier：Tigatuzumab

外部链接

路径

目标

酶

载体

运输工具

药物反应

效应

不良反应